Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
Patients with refractory SCLC. Patients will be treated with paclitaxel and pembrolizumab.
Small Cell Lung Cancer
DRUG: pembrolizumab, paclitaxel
Objective Response Rate, Tumor response will be assessed based on modified RECIST 1.1, 3 months
Progression-free Survival, Tumor response will be assessed based on modified RECIST 1.1, from first dose to disease progression or death due to any cause, whichever came first, up to 24months|Overall Response (OS), Tumor response will be assessed based on modified RECIST 1.1, from first dose to death due to any cause, whichever came first, assessed up to 24 months|Safety(Toxicity), Safety will be assessed for all subjects and documented according to the CTCAE v4.0, 3 months
Number of Participants With Adverse Events as a Measure of Safety and Tolerability, find out predictive biomarker for pembrolizumab. Factors potentially associated with pembrolizumab response will b analyzed for providing the rationale for future patient selection., 3 months
Open, uncontrolled, multi-center, phase II study.